Influence of MWCNT/surfactant dispersions on the rheology of Portland cement pastes

This work studies the effect of MWCNT/surfactant aqueous dispersions on the rheology of cement paste. Three types of surfactants (sodium dodecyl sulfate, cetylpyridinium chloride and triton TX-100) were used to prepare cement pastes with and without MWCNT. Three rheological parameters were determined for each sample: static yield stress, yield stress, and viscosity. The first was measured directly, while the other two were obtained by fitting a Bingham model to the descending portion of a flow curve. Additionally, X-ray diffraction and isothermal calorimetry were used to follow the hydration reaction of cement during the first hour. It was found that the MWCNT/surfactant dispersions generate an overall shift to higher yield stress values while maintaining viscosity, suggesting a modification of the interparticle attraction. It was concluded that the triple interaction MWCNT-surfactant-cement governs the rheology of cement pastes. © 2018 Elsevier Lt

Reinforcing Effect of Carbon Nanotubes/Surfactant Dispersions in Portland Cement Pastes

Decoupling the individual effects of multiwalled carbon nanotubes (MWCNTs) and surfactants when used as reinforcement materials in cement-based composites is aimed in this study. Powder MWCNTs were dispersed in deionized water using different types of surfactants as chemical dispersing agents and an ultrasonic tip processor. Cement pastes with carbon nanotubes additions of 0.15% by mass of cement were produced in two steps: first, the MWCNT/surfactant dispersions were combined with the mixing water, and then, cement was added and mixed until a homogeneous paste was obtained. Mechanical properties of the pastes cured at 7 days were measured, and their fracture behavior was characterized using the linear elastic finite element analysis. It was found that the reinforcing effect of MWCNT was masked by the negative effect of surfactants in the cement matrix; nevertheless, nanotubes were capable of increasing both stress and strain capacity of the composite by controlling the crack propagation process at the tip of the crack. © 2018 Oscar A. Mendoza Reales et al

Enteric methane mitigation strategies for ruminant livestock systems in the Latin America and Caribbean region: a meta-analysis.

Abstract: Latin America and Caribbean (LAC) is a developing region characterized for its importance for global food security,producing 23 and 11% of the global beef and milk production, respectively. The region?s ruminant livestock sector however, is under scrutiny on environmental grounds due to its large contribution to enteric methane (CH4) emissions and influence on global climate change. Thus, the identification of effective CH4 mitigation strategies which do not compromise animal performance is urgently needed, especially in context of the Sustainable Development Goals (SDG) defined in the Paris Agreement of the United Nations. Therefore, the objectives of the current study were to: 1) collate a database of individual sheep, beef and dairy cattle records from enteric CH4 emission studies conducted in the LAC region, and 2) perform a meta-analysis to identify feasible enteric CH4 mitigation strategies, which do not compromise animal performance. After outlier?s removal, 2745 animal records (65% of the original data) from 103 studies were retained (from 2011 to 2021) in the LAC database. Potential mitigation strategies were classified into three main categories (i.e., animal breeding, dietary, and rumen manipulation) and up to three subcategories, totaling 34 evaluated strategies. A random effects model weighted by inverse variance was used (Comprehensive Meta-Analysis V3.3.070). Six strategies decreased at least one enteric CH4 metric and simultaneously increased milk yield (MY; dairy cattle) or average daily gain (ADG; beef cattle and sheep). The breed composition F1 Holstein ×Gyr decreased CH4 emission per MY (CH4IMilk) while increasing MY by 99%. Adequate strategies of grazing management under continuous and rotational stocking decreased CH4 emission per ADG (CH4IGain) by 22 and 35%, while increasing ADG by 22 and 71%, respectively. Increased dietary protein concentration, and increased concentrate level through cottonseed meal inclusion, decreased CH4IMilk and CH4IGain by 10 and 20% and increased MY and ADG by 12 and 31%, respectively. Lastly, increased feeding level decreased CH4IGain by 37%, while increasing ADG by 171%. The identified effective mitigation strategies can be adopted by livestock producers according to their specific needs and aid LAC countries in achieving SDG as defined in the Paris Agreement

Vorapaxar in the secondary prevention of atherothrombotic events

Item does not contain fulltextBACKGROUND: Thrombin potently activates platelets through the protease-activated receptor PAR-1. Vorapaxar is a novel antiplatelet agent that selectively inhibits the cellular actions of thrombin through antagonism of PAR-1. METHODS: We randomly assigned 26,449 patients who had a history of myocardial infarction, ischemic stroke, or peripheral arterial disease to receive vorapaxar (2.5 mg daily) or matching placebo and followed them for a median of 30 months. The primary efficacy end point was the composite of death from cardiovascular causes, myocardial infarction, or stroke. After 2 years, the data and safety monitoring board recommended discontinuation of the study treatment in patients with a history of stroke owing to the risk of intracranial hemorrhage. RESULTS: At 3 years, the primary end point had occurred in 1028 patients (9.3%) in the vorapaxar group and in 1176 patients (10.5%) in the placebo group (hazard ratio for the vorapaxar group, 0.87; 95% confidence interval [CI], 0.80 to 0.94; P<0.001). Cardiovascular death, myocardial infarction, stroke, or recurrent ischemia leading to revascularization occurred in 1259 patients (11.2%) in the vorapaxar group and 1417 patients (12.4%) in the placebo group (hazard ratio, 0.88; 95% CI, 0.82 to 0.95; P=0.001). Moderate or severe bleeding occurred in 4.2% of patients who received vorapaxar and 2.5% of those who received placebo (hazard ratio, 1.66; 95% CI, 1.43 to 1.93; P<0.001). There was an increase in the rate of intracranial hemorrhage in the vorapaxar group (1.0%, vs. 0.5% in the placebo group; P<0.001). CONCLUSIONS: Inhibition of PAR-1 with vorapaxar reduced the risk of cardiovascular death or ischemic events in patients with stable atherosclerosis who were receiving standard therapy. However, it increased the risk of moderate or severe bleeding, including intracranial hemorrhage. (Funded by Merck; TRA 2P-TIMI 50 ClinicalTrials.gov number, NCT00526474.)